Diagnosis and treatment of Wilson disease: An update

Abstract

This guideline has been approved by the American Association for the Study of Liver Diseases (AASLD) and represents the position of the association. PreambleThese recommendations provide a data-supported approach to the diagnosis and treatment of patients with Wilson disease.They are based on the following: (1) formal review and analysis of the recently-published world literature on the topic including Medline search; (2) American College of Physicians Manual for Assessing Health Practices and Designing Practice Guidelines 1 ; (3) guideline policies, including the AASLD Policy on the Development and Use of Practice Guidelines and the American Gastroenterological Association Policy Statement on Guidelines 2 ; ( 4) the experience of the authors in the specified topic.A significant problem with the literature on Wilson disease is that patients are sufficiently rare to preclude large cohort studies or randomized controlled trials; moreover, most treatment modalities were developed at a time when conventions for drug assessment were less stringent than at present.Intended for use by physicians, these recommendations suggest preferred approaches to the diagnostic, therapeutic, and preventive aspects of care.They are intended to be flexible, in contrast to standards of care, which are inflexible policies to be followed in every case.Specific recommendations are based on relevant published information.To characterize more fully the quality of evidence supporting recommendations, the Practice Guidelines Committee of the AASLD requires a class (reflecting ben-efit versus risk) and level (assessing strength or certainty) of evidence to be assigned and reported with each recommendation (Table 1, adapted from the American College of Cardiology and the American Heart Association Practice Guidelines 3,4 ).